Programmed cell death 1/PD‐L1 ICI has shown promising results in patients with NSCLC.20, 21 Apart from clinicopathologic parameters and mutation‐defined molecular phenotypes,22 distinct TMIT is another key impact of clinical prognosis and therapy in lung cancer.23 The rational selection of personalized ICI therapy requires a deeper understanding of TMIT based on PD‐L1 and TIL. The gene discussed is PDCD1; the disease is lung carcinoma.